<?xml version="1.0" encoding="utf-8"?>
<Document>
  <Do_id>19669326</Do_id>
  <Journal>Hepatology international</Journal>
  <Doc_title>Reactivation of chronic hepatitis B infection related to imatinib mesylate therapy.</Doc_title>
  <Doc_abstract>Imatinib (Gleevec, Novartis), an inhibitor of BCR-ABL, platelet-derived growth factor, and KIT receptor tyrosine kinases, is widely used in the treatment of chronic myelogenous leukemia and gastrointestinal stromal tumors. We describe a case of activation of chronic hepatitis B infection associated with imatinib therapy.</Doc_abstract>
  <Doc_ChemicalList>None</Doc_ChemicalList>
  <Doc_meshdescriptors>None</Doc_meshdescriptors>
  <Doc_meshqualifiers>None</Doc_meshqualifiers>
</Document>
